Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) experienced a decline of 0.26% on August 4, with a trading volume of 845 million yuan [1] - The fund's shares decreased by 19 million to a total of 3.504 billion shares, with a reduction of 291 million shares over the last 20 trading days [1] - The latest net asset value of the fund is calculated at 5.355 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Stock Connect Innovative Drug ETF is the adjusted return of the National Index for Hong Kong Stock Connect Innovative Drugs [1] - The fund is managed by ICBC Credit Suisse Asset Management Company, with fund managers Liu Weilin and Jiao Wenlong [1] - Since its establishment on March 26, 2025, the fund has achieved a return of 52.81%, with a one-month return of 16.12% [1]
8月4日港股通创新药ETF工银（159217）份额减少1900.00万份，最新份额35.04亿份，最新规模53.55亿元
Xin Lang Cai Jing·2025-08-05 01:09